Document is current
Any future updates will be listed below
-
Authors
Rathmacher, John A.
Fuller, John C. Jr
Abumrad, Naji N.
Flynn, Charles R.
- License Information
-
More Information
Article History
Received: 27 January 2023
Revised: 28 February 2023
Accepted: 2 March 2023
First Online: 20 March 2023
DECLARATIONS
:
: The study protocol was approved by the Vanderbilt University Institutional Review Board.
: All participants provided written informed consent before participating in the study.
: Not applicable.
: The authors declare the following financial interests/personal relationships which may be considered potential competing interests: John A. Rathmacher, John C. Fuller, Jr., and Charles R. Flynn report financial support was provided by National Institute on Aging. John A. Rathmacher reports financial support was provided by the National Heart, Lung, and Blood Institute. John Rathmacher is employed by MTI Biotech Inc. and is named as an inventor on a number of 2-hydroxybenzylamine patents. MTI Biotech Inc. has a licensing agreement with Vanderbilt University for the future use of electrophile scavenger drugs, including the 2-hydroxybenzylamine. Charles R. Flynn is employed by Vanderbilt University Medical Center and is named as an inventor on a 2-hydroxybenzylamine patent. John C. Fuller, Jr., and Naji N. Abumrad are employed by Metabolic Technologies, LLC. Naji N. Abumrad is the CEO of MTI BioTech Inc.
